Patient non-adherence to drug usage is a major barrier to treating tuberculosis (TB). Telemedicine has shown promise in treatment monitoring and evaluation. This paper aims to explore scientific evidence of telemedicine application in TB treatment to promote widespread adoption in areas that are remote or have poor road networks from health facilities. Articles published from 2010 to 2023 on the adherence and outcomes in pulmonary tuberculosis with the use of telemedicine were reviewed. A scoping review of the studies was conducted by two authors independently, following the PRISMA guidelines to identify relevant articles. Telemedicine interventions have shown improvements in medication adherence, treatment completion, cure rates, and smear conversion among TB patients. The available evidence supports the beneficial effect of telemedicine in improving treatment adherence and outcomes in patients with pulmonary tuberculosis. However, the effect and outcomes varied across studies, indicating the need for further research and standardization of telemedicine interventions.
Patient nonadherence to drug usage is a major barrier to treating Tuberculosis (TB). Telemedicine has shown promise in treatment monitoring and evaluation. This paper aims to explore scientific evidence of telemedicine application in TB treatment to promote widespread adoption in areas that are remote, or with poor road networks from health facilities. Articles published from 2010 to 2023 on the adherence and outcomes in pulmonary tuberculosis with the use of telemedicine were reviewed. A scoping review of the studies was conducted by two authors independently, following the PRISMA guidelines to identify relevant articles. Telemedicine interventions have shown improvements in medication adherence, treatment completion, cure rates, and smear conversion among TB patients. The available evidence supports the beneficial effect of telemedicine in improving treatment adherence and outcomes in patients with pulmonary tuberculosis. However, the effect and outcomes varied across studies, indicating the need for further research and standardization of telemedicine interventions.
Background: The sputum smear test is a key tool in diagnosing and monitoring treatment response in pulmonary tuberculosis (PTB). Despite the implementation of directly observed therapy short course (DOTS), sputum conversion rates have not improved significantly. This highlights the need for enhanced supervision and monitoring, particularly for patients located far from healthcare providers. This study aimed to evaluate the impact of intensive home monitoring of anti-TB drug adherence through telemedicine, specifically using video directly observed therapy (ViDOT). Methodology: This clinical control trial (CCT) involved participants assigned to either the ViDOT or standard DOTS group in a 1:1 ratio. Patients were consecutively recruited in a non-randomized manner and followed for six months. To minimize performance bias, the control group was unaware of the study and did not have access to the monitoring app. Results: A total of 150 patients participated, with ages ranging from 18 to 60 years, and males representing 54% of the cohort. Seventy-two percent of the cases were new TB diagnoses, with the highest prevalence observed in patients aged 31 to 40 years (39.33%), predominantly among those holding a Bachelor’s degree (32.67%). Among patients receiving ViDOT and DOTS, only the presence of comorbidities and adherence to medication significantly affected sputum conversion (P < 0.001). A notable decline in the number of patients without sputum conversion was observed in the ViDOT group, while an increase was noted in the DOTS group. Conclusion: Patients utilizing telemedicine-based DOTS exhibited a higher likelihood of successful sputum conversion by the end of the treatment period compared to those receiving standard DOTS. It is recommended that healthcare systems should consider integrating ViDOT into their existing infrastructure to enhance the monitoring and supervision of anti-TB treatment, ultimately improving sputum conversion rates and treatment outcomes.